FORMA Therapeutics Announces Oncology Collaboration with Novartis
News Jul 30, 2009
FORMA Therapeutics announced that it has entered into a collaboration agreement with Novartis. Under the terms of the agreement, FORMA will utilize its cell-based screening platform to discover inhibitors for undisclosed protein-protein interaction targets in the field of oncology. Financial terms of the collaboration were not disclosed.
“FORMA is pleased to expand its relationship with Novartis beyond our existing agreement with the Novartis Option Fund,” said Steven Tregay, CEO of FORMA. “This collaboration provides additional validation of our fully integrated drug discovery technologies, including our transformative biology and chemistry platforms, which we will use to unlock the elusive protein-protein interaction target class that is so important to oncology drug discovery.”
Worms Exhibit Fear and Respond to Anti-anxiety MedsNews
A team of investigators has uncovered new clues about the mechanisms of fear and anxiety through an unlikely creature: the tiny nematode worm.READ MORE
Low Temperatures Turn Stem Cells into Calorie-Burning FatNews
The secret to healthy eating may not be in freezer food, but low temperatures can help turn stem cells into brown fat, a type of fat which helps burn calories. A new study could turn this knowledge into weight-loss treatments.READ MORE